GD2-positive cells and survival in neuroblastoma
Author Information
Author(s): Corrias M V, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa A R, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, Faulkner L, Garaventa A
Primary Institution: Gaslini Institute
Hypothesis
The presence of GD2-positive cells in bone marrow affects the survival of patients with localized neuroblastoma.
Conclusion
GD2 positivity may serve as a prognostic marker for patients with non-metastatic neuroblastoma, indicating a need for closer follow-up.
Supporting Evidence
- 19 out of 145 patients were found to be GD2-positive.
- 5-year event-free survival for GD2-positive patients was 62.2%, compared to 89.9% for GD2-negative patients.
- GD2 positivity was not associated with other known risk factors like Myc-N amplification.
Takeaway
If kids with neuroblastoma have certain cells in their bone marrow, they might not do as well as those who don't have those cells.
Methodology
The study analyzed bone marrow samples from 145 children diagnosed with localized neuroblastoma using anti-GD2 immunocytochemistry.
Potential Biases
Potential bias due to the retrospective nature of data collection from multiple centers.
Limitations
The small sample size of GD2-positive patients limits the generalizability of the findings.
Participant Demographics
145 Italian children with localized neuroblastoma, ages not specified.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website